C3 and systemic lupus erythematosus: However, a clinical study investigating the use of anti-CD154 antibody for the treatment of SLE was terminated earlier than expected because of thromboembolic events, even though anti-CD154 antibody treatment showed good clinical responses in some SLE patients, with decreased anti-dsDNA antibodies, increased C3 concentration, and decreased hematuria21–23.